Geron Stock Fundamentals
| GERN Stock | USD 1.64 0.03 1.80% |
Geron fundamentals help investors to digest information that contributes to Geron's financial success or failures. It also enables traders to predict the movement of Geron Stock. The fundamental analysis module provides a way to measure Geron's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Geron stock.
At this time, Geron's Research Development is very stable compared to the past year. As of the 15th of March 2025, Total Operating Expenses is likely to grow to about 261.9 M, though Operating Income is likely to grow to (165 M). Geron | Select Account or Indicator |
Geron Company Profit Margin Analysis
Geron's Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current Geron Profit Margin | (2.27) % |
Most of Geron's fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Geron is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Geron Pretax Profit Margin
Pretax Profit Margin |
|
Based on the latest financial disclosure, Geron has a Profit Margin of -2.2674%. This is 79.77% lower than that of the Biotechnology sector and 90.15% lower than that of the Health Care industry. The profit margin for all United States stocks is 78.54% higher than that of the company.
Geron Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Geron's current stock value. Our valuation model uses many indicators to compare Geron value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Geron competition to find correlations between indicators driving Geron's intrinsic value. More Info.Geron is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Geron's Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Geron's earnings, one of the primary drivers of an investment's value.Geron Profit Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Geron's direct or indirect competition against its Profit Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Geron could also be used in its relative valuation, which is a method of valuing Geron by comparing valuation metrics of similar companies.Geron is currently under evaluation in profit margin category among its peers.
Geron Current Valuation Drivers
We derive many important indicators used in calculating different scores of Geron from analyzing Geron's financial statements. These drivers represent accounts that assess Geron's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Geron's important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 431.6M | 399.7M | 921.5M | 1.2B | 2.3B | 2.4B | |
| Enterprise Value | 451.1M | 419.8M | 920.0M | 1.2B | 2.2B | 2.3B |
Geron Fundamentals
| Return On Equity | -0.66 | ||||
| Return On Asset | -0.22 | ||||
| Profit Margin | (2.27) % | ||||
| Operating Margin | (0.42) % | ||||
| Current Valuation | 753.3 M | ||||
| Shares Outstanding | 636.9 M | ||||
| Shares Owned By Institutions | 78.50 % | ||||
| Number Of Shares Shorted | 69.77 M | ||||
| Price To Earning | (12.48) X | ||||
| Price To Book | 3.70 X | ||||
| Price To Sales | 13.57 X | ||||
| Revenue | 76.99 M | ||||
| Gross Profit | (28 M) | ||||
| EBITDA | (154.85 M) | ||||
| Net Income | (174.57 M) | ||||
| Cash And Equivalents | 219.29 M | ||||
| Cash Per Share | 0.58 X | ||||
| Total Debt | 3.24 M | ||||
| Debt To Equity | 0.39 % | ||||
| Current Ratio | 4.85 X | ||||
| Book Value Per Share | 0.46 X | ||||
| Cash Flow From Operations | (218.62 M) | ||||
| Short Ratio | 3.32 X | ||||
| Earnings Per Share | (0.27) X | ||||
| Price To Earnings To Growth | (2.38) X | ||||
| Target Price | 4.5 | ||||
| Number Of Employees | 229 | ||||
| Beta | 0.53 | ||||
| Market Capitalization | 1.04 B | ||||
| Total Asset | 593.78 M | ||||
| Retained Earnings | (1.77 B) | ||||
| Working Capital | 402.69 M | ||||
| Current Asset | 115.89 M | ||||
| Current Liabilities | 6.63 M | ||||
| Net Asset | 593.78 M |
About Geron Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Geron's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Geron using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Geron based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 40.2 M | 42.3 M | |
| Total Revenue | 77 M | 80.8 M | |
| Cost Of Revenue | 1.3 M | 1.2 M | |
| Sales General And Administrative To Revenue | 1.89 | 1.80 | |
| Research And Ddevelopement To Revenue | 1.35 | 1.28 | |
| Capex To Revenue | 0.01 | 0.01 | |
| Revenue Per Share | 0.12 | 0.15 | |
| Ebit Per Revenue | (2.26) | (2.37) |
Check out Geron Piotroski F Score and Geron Altman Z Score analysis. To learn how to invest in Geron Stock, please use our How to Invest in Geron guide.You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Geron. If investors know Geron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Geron listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.27) | Revenue Per Share | Quarterly Revenue Growth 2.1 K | Return On Assets | Return On Equity |
The market value of Geron is measured differently than its book value, which is the value of Geron that is recorded on the company's balance sheet. Investors also form their own opinion of Geron's value that differs from its market value or its book value, called intrinsic value, which is Geron's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Geron's market value can be influenced by many factors that don't directly affect Geron's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Geron's value and its price as these two are different measures arrived at by different means. Investors typically determine if Geron is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Geron's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.